The deal is done. Diagnostic test maker Quidel now officially owns BioHelix, a Beverly, MA maker of nucleic acid technology for molecular diagnostic tests. Quidel is paying $10 million in cash up front, plus more money depending on a number of development and sales milestones.
Quidel has its latest molecular diagnostic test approval in hand, this time a CE mark for a blood test that screens for herpes plus a virus that causes chicken pox and shingles.
Quidel won a coveted 510(k) clearance from the FDA for a new hand-held molecular diagnostic test to detect DNA for Clostridium difficile bacteria.
Quidel ($QDEL) has received the CE mark for its first molecular diagnostic test, the Influenza A+B real-time RT-PCR assay. The CE mark allows for the launch of the open box molecular platform in